Prof. Dr. Dr. med. Antonio Cozzio
Chefarzt/Chefärztin
Dermatologie | Venerologie | Allergologie · Dept. IV
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
14.02.2022
Klinische Forschung - 14.02.2022 - 31.12.2025
Laufend
Projektleitung: Cozzio Antonio
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study
25.01.2022
Klinische Forschung - 25.01.2022 - 25.01.2022
Automatisch geschlossen
Projektleitung: Cozzio Antonio
Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate -to -severe plaque psoriasis and inadequate response to ustekinumab; COBRA / Phase 4 – efficacy trial A randomised, blinded, parallel-group, multi-site, clinical trial
13.09.2021
Klinische Forschung - 13.09.2021 - 16.11.2022
Abgeschlossen
Projektleitung: Cozzio Antonio
Development of the European Organisation for Research and Treatment of Cancer (EORTC)/ Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma
01.02.2021
Klinische Forschung - 01.02.2021 - 25.08.2023
Automatisch geschlossen
Projektleitung: Cozzio Antonio
A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
25.06.2016
Klinische Forschung - 25.06.2016 - 31.12.2027
Laufend
Projektleitung: Cozzio Antonio
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
31.01.2012
Klinische Forschung - 31.01.2012 - 31.12.2030
Laufend
Projektleitung: Cozzio Antonio